Statement of Changes in Beneficial Ownership (4)

FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5
	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person * BRANCACCIO JOHN P	2. Issuer Name and Ticker or Trading Symbol Cardiff Oncology, Inc. [ CRDF ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) _____ Director                    _____ 10% Owner _____ Officer (give title below)    __X__ Other (specify below) Former Director
(Last)          (First)          (Middle) C/O CARDIFF ONCOLOGY, INC., 11055 FLINTKOTE AVENUE	3. Date of Earliest Transaction (MM/DD/YYYY) 6/9/2022
(Street) SAN DIEGO, CA 92121 (City)        (State)        (Zip)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line) _X _ Form filed by One Reporting Person ___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security (Instr. 3)	2. Trans. Date	2A. Deemed Execution Date, if any	3. Trans. Code (Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date	3A. Deemed Execution Date, if any	4. Trans. Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$2.5	6/9/2022		J (1)		26800		6/9/2022	6/9/2024	Common Stock	26800.0	$0	125317	D
Stock Options	$7.98	6/9/2022		J (2)		22000		6/9/2022	6/9/2024	Common Stock	22000.0	$0	125317	D
Stock Options	$2.6	6/9/2022		J (3)		28858		6/17/2021	6/9/2024	Common Stock	28858.0	$0	125317	D
Stock Options	$2.48	6/9/2022		J (3)		44734		6/20/2020	6/9/2024	Common Stock	44734.0	$0	125317	D
Stock Options	$21.6	6/9/2022		J (3)		755		1/23/2019	6/9/2024	Common Stock	755.0	$0	125317	D
Stock Options	$51.84	6/9/2022		J (3)		530		10/4/2018	6/9/2024	Common Stock	530.0	$0	125317	D
Stock Options	$372.96	6/9/2022		J (3)		223		1/4/2017	6/9/2024	Common Stock	223.0	$0	125317	D
Stock Options	$516.96	6/9/2022		J (3)		223		3/17/2016	6/9/2024	Common Stock	223.0	$0	125317	D
Stock Options	$316.08	6/9/2022		J (3)		195		12/11/2014	6/9/2024	Common Stock	195.0	$0	125317	D

Explanation of Responses:
(1)	In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 26,800 stock options to June 9, 2022 from March 9, 2023. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
(2)	In connection with the Reporting Person's departure from the Board of Directors, the Compensation Committee accelerated the vesting of 22,000 stock options to June 9, 2022 from June 10, 2022. In addition, the Compensation Committee extended the expiration date of the stock options to June 9, 2024.
(3)	Expiration date of the stock options was extended to June 9, 2024.

Reporting Owners
Reporting Owner Name / Address	Relationships
	Director	10% Owner	Officer	Other
BRANCACCIO JOHN P C/O CARDIFF ONCOLOGY, INC. 11055 FLINTKOTE AVENUE SAN DIEGO, CA 92121				Former Director

Signatures
/s/ John Brancaccio		6/9/2022
**Signature of Reporting Person		Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*	If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**	Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:	File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.